G. A. Mavzyutova

G. A. Mavzyutova

Auto-generated profile, based on publicly available information

G. A. Mavzyutova

Bashkir State Medical University

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2014 in Medical Immunology (Russia)
Verified
Journal Article
Open access
PDF file
LML. R. Mukhamadieva
L. R. Mukhamadieva
GMG. A. Mavzyutova
G. A. Mavzyutova
RFR. M. Fazlyeva
R. M. Fazlyeva
NBN. R. Bikhmetova
N. R. Bikhmetova
КЛИНИКО-ИММУНОЛОГИЧЕСКАЯ ЭФФЕКТИВНОСТЬ ИМУНОФАНА И ПОЛИОКСИДОНИЯ В КОМПЛЕКСНОЙ ТЕРАПИИ ВНЕБОЛЬНИЧНОЙ ПНЕВМОНИИ

1 December 2015
Verified
Journal Article
Closed access
GMG A Mavzyutova
G A Mavzyutova
OKO Z Kuzovkina
O Z Kuzovkina
IMI A Mirsayapova
I A Mirsayapova


13 April 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
GGG. A. Galieva
G. A. Galieva
GMG. Kh. Mirsaeva
G. Kh. Mirsaeva
GMG. A. Mavzyutova
G. A. Mavzyutova
NMN. N. Mironchuk
N. N. Mironchuk
LAL. Kh. Amineva
L. Kh. Amineva
GGGuzel Galieva
Guzel Galieva
Introduction. The study of the manifestations of symptoms of COVID-19 and hemorrhagic fever with renal syndrome (HFRS) is an important aspect of the diagnosis, especially for regions endemic for HFRS.Aim. To conduct сomparative study of the clinical symptoms and parametres of a complete blood test at the onset of the disease with lung involvement in patients with HFRS and COVID-19 with moderate severity.Materials and methods. A retrospective comparative analysis and identification of laboratory data of patients with moderate form of HFRS with respiratory syndrome (n = 52) and patients with moderate severity form of COVID-19 (n = 52) upon admission to the hospital was carried out.Results. Fever is one of the main symptoms for both diseases, characterizing the degree of severity. At the same time, the temperature in patients with HFRS on admission was higher than in patients with COVID-19 (p < 0.05). Shortness of breath is much more often recorded in the group of patients with viral pneumonia COVID-19 (p = 0.0001). The oxygen saturation index (SpO2) in patients with HFRS was below 95%, but the average value of 96.4% was normal, while in patients with COVID-19 the average value was 92.8% (p < 0.05). When comparing the indicators of the general blood test, there was a statistically significant excess of the level of red blood cells and hematocrit in the group of patients with COVID-19, with a comparable level of hemoglobin in both groups. The average value of the absolute content of platelets was significantly lower, and the number of patients with thrombocytopenia is much higher in the group of patients with HFRS.Conclusion. Kidney damage in HFRS is the main clinical and laboratory syndrome, but it is important to remember that lung damage by the type of viral pneumonia in HFRS is also possible. In all suspicious cases, an examination for SARS-CoV-2 and serological diagnosis of hantavirus infection are indicated.

15 May 2026 in Science Journal of Clinical Medicine
Verified
Journal Article
Closed access
MRMukhamadieva Ramilevna
Mukhamadieva Ramilevna
MAMavzyutova Anvarovna
Mavzyutova Anvarovna
MKMirsaeva Khanifovna
Mirsaeva Khanifovna
AVAleksandrovich Victorovna
Aleksandrovich Victorovna
IAIbragimova Aleksandrovna
Ibragimova Aleksandrovna
UVUmutbaev Vilsamovich
Umutbaev Vilsamovich
The study assessed the efficacy and safety of Longidaza® (bovhyaluronidase azoximer, 3000 IU) in patients with lung damage after complicated COVID‑19. Two groups of 30 patients each were compared: the first received Longidaza® via intramuscular injections (3000 IU every five days, 15 injections total); the second was under dynamic observation without active therapy. The trial ran from August to December 2023. Participants were over 18 years old, had lung manifestations after severe COVID‑19, started outpatient treatment within two months after hospital discharge, and provided informed consent. Exclusion criteria included pregnancy, lactation, severe comorbidities, etc. Key parameters after 10 weeks (day 71) were changes in: resting capillary blood oxygen saturation (SpO 2 ,%); laboratory markers (lymphocytes, C‑reactive protein [CRP], D-dimer, fibrinogen). Statistical analysis used Stata 14.0 (significance level: p < 0,05; Mann‑Whitney test). Mean age was 59.8 ± 15.2 years (Longidaza group) and 56.06 ± 13.7 years (observation group). Common comorbidities: hypertension and coronary heart disease. Results: CRP levels decreased more than twofold in both groups (to 3.66 ± 3.84 mg/L and 1.24 ± 0.7 mg/L, respectively). Blood oxygen saturation stayed ≥ 96% in most patients. In the Longidaza group, some parameters were statistically significantly lower — possibly indicating antifibrotic activity. No adverse effects were reported. Conclusion: Longidaza® is safe and potentially effective for preventing and treating early pneumofibrosis and managing established lung fibrosis.

15 January 2020 in Russian Clinical Laboratory Diagnostics
Verified
Journal Article
Open access
AMA. R. Mavzyutov
A. R. Mavzyutov
KBK. R. Bondarenko
K. R. Bondarenko
GMG. A. Mavzyutova
G. A. Mavzyutova
LGL. R. Glazutdinova
L. R. Glazutdinova
The review systematizes data on the structure of lipopolysaccharides (LPS) and their role in physiological and systemic pathological processes. The analysis of literature and our own data is of scientific and practical interest for specialists in the field of clinical laboratory diagnostics, anesthesiologists, resuscitators, therapists, immunologists and obstetrician-gynecologists, including studies on the role of LPS in unique three-component systems - «mother-placenta-fetus». The prospects of using LPS as immunomodulatory, including for the treatment of infectious diseases, are justified. It is shown that along with their use for the correction of immunodeficiency or the development of new adjuvants and vaccines, it is possible to use their high regulatory activity even at the epigenetic level. The possibility of the prophylactic and therapeutic use of LPS in the context of an alternative solution to the problem of antibiotic resistance of bacteria is discussed.